Geopolitics, policy, and the new global landscape for Advanced Therapies

Advanced therapies are being reshaped by geopolitics, funding shifts, and emerging regional capabilities. U.S. momentum behind mRNA research is softening, creating downstream challenges for innovation and manufacturing, while advocacy groups work to maintain regulatory clarity and ecosystem strength. At the same time, APAC nations are rapidly building end-to-end platforms and coordinated trial networks, creating a more multipolar landscape. This session explores how these forces will influence supply chains, standards, and global access.